BriaCell Partners with Caris Life Sciences to Expand Patient Outreach and Molecular Profiling

BriaCell Therapeutics Corp. announces that it has signed an agreement with Caris Life Sciences (Caris).

“Our goal is to develop immunotherapies that are personalized for each patient, and Caris’ extensive library of clinical data, cutting-edge biomarker technology, and expertise will be invaluable in achieving our objectives,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We expect Caris’ unique platform to help us identify patients who do not respond to existing treatments and are more likely to benefit from our immunotherapy treatments.”

Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups. The partnership between BriaCell and Caris leverages Caris’ Right-In-Time (RIT) Clinical Trial Network, a group of over 495 oncology sites that are able to quickly identify and enroll eligible patients in biomarker-directed clinical trials. This service offers patients and physicians access to the most cutting-edge precision medicine in development. Additionally, through Caris’ comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing), Caris will perform tumor profiling for the patients enrolled in the clinical trial.